(+)-VINCRISTINE
Stage III Adenoid Cystic Carcinoma of the Oral Cavity
National Cancer Institute (NCI)Small moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Stage III Adenoid Cystic Carcinoma of the Oral Cavity cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Recombinant Interleukin-12 National Cancer Institute (NCI) | Phase 1 | CC |
TRASTUZUMAB National Cancer Institute (NCI) | Phase 1 | CC |
Alvespimycin National Cancer Institute (NCI) | Phase 1 | CC |
Carboplatin National Cancer Institute (NCI) | Phase 1 | CC |
Abi-007 National Cancer Institute (NCI) | Phase 1 | CC |
Same molecule, other indications
(+)-VINCRISTINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →